Thalia Therapeutics Plc (AIM:THAT)

London · Delayed Price · Currency is GBP · Price in GBX

0.6000

-0.0250 (-4.00%)

Oct 15, 2026, 3:31 PM GMT

Market Cap	10.65M +113.4%
Revenue (ttm)	7.22K +2.1%
Net Income	-1.46M
EPS	-0.00
Shares Out	1.78B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,921
Open	0.6394
Previous Close	0.6250
Day's Range	0.6000 - 0.6394
52-Week Range	0.4000 - 0.9500
Beta	0.71
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About Thalia Therapeutics

Thalia Therapeutics Plc, a biotechnology company, develops and delivers RNA-based therapeutics and technologies in oncology and cardiovascular disease in the United Kingdom. The company develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines. It also develops Nuvec, a pipeline of RNA therapeutics; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation in... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1979

Employees 3

Stock Exchange London Stock Exchange AIM

Ticker Symbol THAT

Full Company Profile

Financial Performance

In 2025, Thalia Therapeutics's revenue was 7,264, a decrease of -0.25% compared to the previous year's 7,282. Losses were -1.21 million, 13.8% more than in 2024.

Financial Statements